Treatment for Prurigo
The treatment of prurigo depends critically on identifying and addressing the underlying cause, but when prurigo nodularis (chronic prurigo) is the primary diagnosis, start with emollients and topical corticosteroids, then escalate to dupilumab as the first FDA-approved systemic therapy, or consider gabapentin, antihistamines, or phototherapy based on disease severity and patient factors. 1, 2
Initial Assessment and Diagnosis
The term "prurigo" encompasses different conditions that require distinct treatment approaches. First, determine whether you're dealing with:
- Prurigo nodularis (PN): Firm, nodular lesions with pruritus lasting ≥6 weeks and history of repeated scratching 3
- Generalized pruritus without underlying dermatosis: Requires investigation for systemic causes 1
- Acute/subacute prurigo: Duration <6 weeks 4
For chronic prurigo nodularis, assess disease severity using:
- Peak/worst itch intensity (Numerical Rating Scale, target NRS ≤3 for control) 5
- Number and extent of nodular lesions
- Impact on sleep and quality of life
- Disease burden using validated tools (DLQI, IGA) 5
Treatment Algorithm for Prurigo Nodularis
First-Line Therapy
Start all patients with:
- Emollients (high lipid content preferred) 1
- Medium-to-high potency topical corticosteroids for at least 2 weeks 1, 6
This addresses the immediate inflammatory component and provides symptomatic relief while you determine next steps.
Second-Line Systemic Therapy
When topical therapy fails after 2-4 weeks, escalate based on severity:
For moderate-to-severe disease (NRS ≥7):
- Dupilumab is the only FDA-approved systemic therapy for PN and should be strongly considered as first-line systemic treatment 2, 4
- Targets IL-4 and IL-13 pathways
- Demonstrated sustained efficacy over 68 weeks
- Addresses both neural and immunologic components
Alternative systemic options (all off-label):
- Gabapentin (oral): Effective for neuropathic component 1
- Non-sedating antihistamines: Fexofenadine 180 mg or loratadine 10 mg 1
- Consider H1 + H2 antagonist combination (e.g., fexofenadine + cimetidine) 1
- Mirtazapine: Addresses both itch and sleep disturbance 1
- SSRIs (paroxetine, fluvoxamine, sertraline): Target central itch pathways 1
Important caveat: Avoid long-term sedating antihistamines (except in palliative care) as they may predispose to dementia 1
Third-Line Therapy
Phototherapy:
- Narrowband UVB (NB-UVB) is effective for many patients with chronic prurigo 1
- Broadband UVB (BB-UVB) or combined UVA/UVB are alternatives 1
- Can be used in combination with systemic therapy
Additional systemic options:
Topical Adjuncts
Consider adding:
- Topical doxepin (limit to 8 days, 10% body surface area, 12g daily maximum) 1
- Topical menthol or clobetasone butyrate 1
- Capsaicin cream (for localized disease) 1
Avoid: Crotamiton cream (ineffective, Strength B recommendation) and calamine lotion 1
Treatment Goals and Monitoring
Target these specific endpoints (treat-to-target criteria): 5
- Itch control: NRS ≤3
- Lesion healing: IGA score 0/1 (clear or almost clear)
- Improved sleep quality
- Reduced disease burden and improved quality of life
If targets not met within 12-16 weeks, switch or add therapy rather than continuing ineffective treatment 5
Special Considerations
For elderly patients with prurigo:
- Start with emollients and topical steroids for 2 weeks to exclude asteatotic eczema 1
- Gabapentin may be beneficial 1
- Absolutely avoid sedating antihistamines (Strength C recommendation) 1
When systemic causes are suspected:
- Iron deficiency: Iron replacement (Strength C) 1
- Hepatic pruritus: Rifampicin first-line (Strength A), then cholestyramine, then sertraline 1
- Uremic pruritus: BB-UVB is highly effective (Strength A); optimize dialysis parameters first 1
- Drug-induced: Trial cessation if risk-benefit acceptable 1
Common Pitfalls
- Treating prurigo as simple eczema: PN requires addressing both neural and immunologic pathways simultaneously 3, 2
- Underdosing or inadequate trial duration: Give systemic therapies adequate time (12-16 weeks) before declaring failure 5
- Using sedating antihistamines long-term: This increases dementia risk without proven efficacy 1
- Missing underlying systemic disease: Always investigate for iron deficiency, liver disease, renal disease, thyroid disorders, and malignancy 1
- Monotherapy failure without escalation: Combination therapy is often necessary for adequate control 2
Emerging Therapies
Nemolizumab (IL-31 antagonist) shows sustained efficacy over 68 weeks with continuous improvement in pruritus (78.6% reduction in PP-NRS), disease severity, and quality of life, allowing reduction in topical corticosteroid use by at least 50% 6. Multiple other biologics and JAK inhibitors are in clinical trials 7, 4.
Referral to dermatology is warranted when:
- Diagnostic uncertainty exists
- Primary care management fails to relieve symptoms after 2-4 weeks
- Systemic therapy or phototherapy is needed 1